Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-14

I think I like many were mindful if not SHxxscared of what expenses were going to like like. I guess the market was expecting worse so at least some comfort they were within coee of guidance this time. FDA response should be a catalyst for more consolidation in the SP and hopefully a move back toward 40c? Once this happens, I hope the board and corporate governance around management is sorted. I believe this in itself will be a significant catalyst for the company. All this in place and I believe they will get their phase 3 done and TGA submission, it's just about the funding and how non-dilutive it can be without adversely affecting future revenues too much. GLTA